- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- Q901, KEYTRUDA® (pembrolizumab)
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
- Interventions
- Q702, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Louisville, Kentucky
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Q301 Cream, Placebo
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Berlin, New Jersey • East Windsor, New Jersey + 4 more
- Conditions
- Healthy Volunteers
- Interventions
- Q203, Placebo
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Venetoclax, Q702
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteers
- Interventions
- Q203, Placebo
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer
- Interventions
- Q702
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Morristown, New Jersey
- Conditions
- Atopic Dermatitis
- Interventions
- Q301 Cream, Vehicle
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina